These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2248211)

  • 61. Captopril versus placebo in congestive heart failure: effects on oxygen delivery to exercising skeletal muscle.
    Timmis AD; Bojanowski LM; Najm YC; Nelson DJ; Gosling RG
    Eur Heart J; 1987 Dec; 8(12):1295-304. PubMed ID: 3325289
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hospital treatment of congestive heart failure. Management according to hemodynamic profile.
    Forrester JS; Waters DD
    Am J Med; 1978 Jul; 65(1):173-80. PubMed ID: 685990
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.
    Townend JN; Doran J; Lote CJ; Davies MK
    Br Heart J; 1995 May; 73(5):434-41. PubMed ID: 7786658
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure.
    Nakamura M; Yoshida H; Makita S; Arakawa N; Niinuma H; Hiramori K
    Circulation; 1997 Mar; 95(5):1214-21. PubMed ID: 9054852
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Conversion enzyme inhibitors in the treatment of chronic congestive cardiac failure. Physiopathologic bases of their use].
    Garabedian VG
    Presse Med; 1985 Dec; 14(44):2264-7. PubMed ID: 3003732
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reassessing the use of vasodilators in heart failure.
    Cole RT; Gheorghiade M; Georgiopoulou VV; Gupta D; Marti CN; Kalogeropoulos AP; Butler J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1141-51. PubMed ID: 23098150
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Organ blood flow protection in hypertension and congestive heart failure.
    Saxena PR; Schoemaker RG
    Am J Med; 1993 Apr; 94(4A):4S-12S. PubMed ID: 8488855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Symposium on vasodilator and inotropic therapy of heart failure. Symposium perspective.
    Mason DT
    Am J Med; 1978 Jul; 65(1):101-5. PubMed ID: 356597
    [No Abstract]   [Full Text] [Related]  

  • 70. Regional blood flow, muscle strength and skeletal muscle histology in severe congestive heart failure.
    Poole-Wilson PA; Buller NP; Lipkin DP
    Am J Cardiol; 1988 Sep; 62(8):49E-52E. PubMed ID: 3414537
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Coronary and renal circulation in patients with cardiac failure after converting enzyme inhibitors].
    Juliard JM; Dahan M; Solal AC; Merillon JP; Gourgon R
    Presse Med; 1985 Dec; 14(44):2260-3. PubMed ID: 3003731
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    Chatterjee K; Massie B; Rubin S; Gelberg H; Brundage BH; Ports TA
    Am J Med; 1978 Jul; 65(1):134-45. PubMed ID: 99031
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Treatment of heart failure: status of therapy with vasodilator agents].
    Just H
    Herz; 1987 Dec; 12 Suppl 1():22-6. PubMed ID: 3436615
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Drug treatment of heart insufficiency].
    Follath F
    Schweiz Med Wochenschr; 1988 Dec; 118(50):1886-91. PubMed ID: 3065935
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Congestive heart failure: is the heart or periphery at fault?
    Cohn JN
    Cardiovasc Drugs Ther; 1987 Aug; 1(2):191-3. PubMed ID: 3154323
    [No Abstract]   [Full Text] [Related]  

  • 76. Electro-metabolic signaling.
    Longden TA; Lederer WJ
    J Gen Physiol; 2024 Feb; 156(2):. PubMed ID: 38197953
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pathophysiology of pediatric heart failure.
    Auslender M
    Prog Pediatr Cardiol; 2000 Sep; 11(3):175-184. PubMed ID: 10978710
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Where Is the "Optimal" Fontan Hemodynamics?
    Ohuchi H
    Korean Circ J; 2017 Nov; 47(6):842-857. PubMed ID: 29035429
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Exercise training normalizes renal blood flow responses to acute hypoxia in experimental heart failure: role of the α1-adrenergic receptor.
    Pügge C; Mediratta J; Marcus NJ; Schultz HD; Schiller AM; Zucker IH
    J Appl Physiol (1985); 2016 Feb; 120(3):334-43. PubMed ID: 26607245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure.
    Kozdağ G; Yaymacı M; Ertaş G; Celikyurt U; Sahin T; Kılıç T; Ural D
    Heart Vessels; 2012 Nov; 27(6):568-75. PubMed ID: 21909806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.